Evidence map›Paper›PMID 40083164›Full record

ArticleBritish journal of clinical pharmacology2025

Pharmacokinetics of betamethasone in pre-eclampsia: An in vivo and ex vivo study.

Sam Schoenmakers, Letao Li, Anna C M Kluivers, Michelle Broekhuizen, Madhavi S Harhangi, A H Jan Danser, Irwin Reiss, Karel Allegaert, Sjoerd A A van den Berg, Bertrand D van Zelst and 6 more

Abstract read
In one paragraph

Article in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Effects of Common Therapies for Threatened Preterm Labor on the Placental Inflammatory Response.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sam SchoenmakersDepartment of Obstetrics and Gynaecology, Division of Obstetrics and Fetal Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0002-0316-6159
Letao LiDepartment of Hospital Pharmacy, Erasmus University Medical Center, The Netherlands.ORCID https://orcid.org/0000-0002-4692-9689
Anna C M KluiversDepartment of Obstetrics and Gynaecology, Division of Obstetrics and Fetal Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0002-4115-372X
Michelle BroekhuizenDepartment of Internal Medicine, Division of Pharmacology and Vascular Medicine, Erasmus MC University Hospital, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-4736-398X
Madhavi S HarhangiDepartment of Obstetrics and Gynaecology, Division of Obstetrics and Fetal Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0001-5814-1103
A H Jan DanserDepartment of Internal Medicine, Division of Pharmacology and Vascular Medicine, Erasmus MC University Hospital, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-5052-3585
Irwin ReissDepartment of Pediatrics, Division of Neonatology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-9474-6895
Karel AllegaertDepartment of Hospital Pharmacy, Erasmus University Medical Center, The Netherlands.ORCID https://orcid.org/0000-0001-9921-5105
Sjoerd A A van den BergDepartment of Internal Medicine, Division of Endocrinology, Erasmus University Medical Center, the Netherlands.ORCID https://orcid.org/0000-0001-5937-7505
Bertrand D van ZelstDepartment of Internal Medicine, Division of Endocrinology, Erasmus University Medical Center, the Netherlands.ORCID https://orcid.org/0000-0001-9148-399X
Ron H N van SchaikDepartment of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0003-1864-2151
Philip L J DeKoninckDepartment of Obstetrics and Gynaecology, Division of Obstetrics and Fetal Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0002-4457-0940
Emma RondeDepartment of Obstetrics and Gynaecology, Division of Obstetrics and Fetal Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0001-9277-5361
Sebastiaan D T SassenDepartment of Hospital Pharmacy, Erasmus University Medical Center, The Netherlands.ORCID https://orcid.org/0000-0002-4525-638X
Sinno H P SimonsDepartment of Pediatrics, Division of Neonatology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0001-5219-5696
Birgit C P KochDepartment of Hospital Pharmacy, Erasmus University Medical Center, The Netherlands.ORCID https://orcid.org/0000-0002-1202-3643

Funding

China Scholarship Council 201908500113
6 · The paper itself

Abstract

aimsTo enhance understanding of betamethasone and its metabolites' pharmacokinetics in pregnancy, specifically early-onset pre-eclampsia, through a population pharmacokinetic model. Additionally, to investigate the placental metabolism and transfer of betamethasone and its main metabolites.

methodsA prospective, single-centre pharmacokinetic study was conducted in pregnant women (n = 28) with imminent preterm birth treated with intramuscular betamethasone. Betamethasone serum concentrations were determined from serial venous blood samples (n = 194). Placental transfer and metabolism were studied using ex vivo human placental perfusion (healthy term; n = 3) and placental explant experiments (healthy term, n = 4; early-onset pre-eclampsia, n = 4). Additionally, placental mRNA expression of CYP3A4, CYP3A7, 11β-hydroxysteroid dehydrogenase (HSD) 1 and 11β-HSD2 were quantified in healthy and early-onset pre-eclampsia placentas.

resultsThe population pharmacokinetic model was best described by a 2-compartment nonlinear mixed effects model. Betamethasone clearance in early-onset pre-eclamptic women was 60% lower of that observed in women without pre-eclampsia (9.35 vs. 15.78 L/h), resulting in a 40% median increase in maternal betamethasone exposure (1567 vs. 1114 ng h/mL). Ex vivo experiments showed placental transfer of betamethasone to the foetal circulation (foetal-to-maternal ratio 0.76 ± 0.05 [in a perfused placental cotyledon]). The placenta only converted betamethasone into 11-ketobetamethasone, with similar ratios in early-onset pre-eclampsia and healthy placental explants (3.0 ± 2.2 vs. 1.4 ± 0.4 per mg tissue, P = .27). The expression of 11β-HSD1 mRNA was lower in early-onset pre-eclampsia placentas (P = .015), while placental CYP3A7 and 11β-HSD2 mRNA expression were similar.

conclusionWomen with early-onset pre-eclampsia have elevated betamethasone exposure. Betamethasone transfers freely into the foetal circulation, with placental metabolism resulting only in 11-ketobetamethasone. Decreased placental 11β-HSD1 expression may play a role in increased betamethasone exposure in early-onset pre-eclampsia.

Indexed as

BetamethasoneGlucocorticoidsPlacentaPre-EclampsiaAdultFemaleHumansMaternal-Fetal ExchangeModels, BiologicalPregnancyProspective StudiesRNA, MessengerYoung AdultBetamethasoneGlucocorticoidsRNA, Messengerantenatal corticosteroidsbetamethasonepopulation pharmacokineticspre‐eclampsiapreterm birth

Identifiers

PMID40083164
PMCPMC12304831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.